Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors
BK Samulitis, KW Pond, E Pond, AE Cress… - Cancer biology & …, 2015 - Taylor & Francis
Gemcitabine based treatment is currently a standard first line treatment for patients with
advanced pancreatic cancer, however overall survival remains poor, and few options are …
advanced pancreatic cancer, however overall survival remains poor, and few options are …
[HTML][HTML] Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin
D Zechner, F Bürtin, AC Albert, X Zhang, S Kumstel… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Cancer heterogeneity and microenvironmental aspects within a tumor are considered key
factors influencing resistance of carcinoma cells to distinct chemotherapeutical agents. We …
factors influencing resistance of carcinoma cells to distinct chemotherapeutical agents. We …
Challenges of drug resistance in the management of pancreatic cancer
R Sheikh, N Walsh, M Clynes, R O'Connor… - Expert review of …, 2010 - Taylor & Francis
The current treatment of choice for metastatic pancreatic cancer involves single-agent
gemcitabine or a combination of gemcitabine with capecitabine or erlotinib (a tyrosine …
gemcitabine or a combination of gemcitabine with capecitabine or erlotinib (a tyrosine …
Everolimus Inhibits Growth of Gemcitabine‐Resistant Pancreatic Cancer Cells via Induction of Caspase‐Dependent Apoptosis and G2/M Arrest
T Peng, QP Dou - Journal of Cellular Biochemistry, 2017 - Wiley Online Library
Pancreatic cancer is the fourth leading cause of cancer‐related death in the United States.
While Gemcitabine‐based chemotherapy is the first‐line treatment for locally advanced …
While Gemcitabine‐based chemotherapy is the first‐line treatment for locally advanced …
Drugs in preclinical and early-stage clinical development for pancreatic cancer
S Asuthkar, JS Rao, CS Gondi - Expert opinion on investigational …, 2012 - Taylor & Francis
Introduction: Pancreatic cancer (PC) is the fourth leading cause of cancer-related deaths in
the US and Europe, and the lethality of this cancer is demonstrated by the fact that the …
the US and Europe, and the lethality of this cancer is demonstrated by the fact that the …
Mass spectrometry-based metabolic profiling of gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells
Y Fujimura, N Ikenaga, K Ohuchida, D Setoyama… - Pancreas, 2014 - journals.lww.com
Objectives Gemcitabine resistance (GR) is one of the critical issues for therapy for pancreatic
cancer, but the mechanism still remains unclear. Our aim was to increase the understanding …
cancer, but the mechanism still remains unclear. Our aim was to increase the understanding …
Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer
E Hessmann, MS Patzak, L Klein, N Chen, V Kari… - Gut, 2018 - gut.bmj.com
Objective Desmoplasia and hypovascularity are thought to impede drug delivery in
pancreatic ductal adenocarcinoma (PDAC). However, stromal depletion approaches have …
pancreatic ductal adenocarcinoma (PDAC). However, stromal depletion approaches have …
The microbiome of pancreatic cancer: from molecular diagnostics to new therapeutic approaches to overcome chemoresistance caused by metabolic inactivation of …
ATF Choy, I Carnevale, S Coppola… - Expert review of …, 2018 - Taylor & Francis
Introduction: Pancreatic cancer is a complex disease, with an extremely poor response to
chemotherapy. Emerging evidence indicates that the tumor microenvironment (TME) might …
chemotherapy. Emerging evidence indicates that the tumor microenvironment (TME) might …
Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer
L de Sousa Cavalcante, G Monteiro - European journal of pharmacology, 2014 - Elsevier
Gemcitabine is the first-line treatment for pancreatic adenocarcinoma, but is increasingly
used to treat breast, bladder, and non-small cell lung cancers. Despite such broad use …
used to treat breast, bladder, and non-small cell lung cancers. Despite such broad use …
Extracellular matrix composition modulates the responsiveness of differentiated and stem pancreatic cancer cells to lipophilic derivate of gemcitabine
S Forciniti, E Dalla Pozza, MR Greco… - International journal of …, 2020 - mdpi.com
Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease.
Gemcitabine (GEM) is used as the gold standard drug in PDAC treatment. However, due to …
Gemcitabine (GEM) is used as the gold standard drug in PDAC treatment. However, due to …